Evaluation of cellular proliferation markers in patients with myelodysplastic syndromes.

被引：0
|
作者：
Ismail, SO
Mutema, G
Perrotta, G
Hornback, B
Wibowo, A
Mazzella, F
KowalVern, A
Schumacher, HR
机构：
[1] UNIV CINCINNATI,MED CTR,DEPT PATHOL & LAB MED,CINCINNATI,OH 45267
[2] LOYOLA UNIV,MED CTR,MAYWOOD,IL 60153
来源：
BLOOD | 1997年 / 90卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：4040 / 4040
页数：1
相关论文
共 50 条
  • [41] ACUTE MYELOID LEUKEMIA PROGRESSION IN ARGENTINEAN PATIENTS WITH MYELODYSPLASTIC SYNDROMES.
    Enrico, A.
    Flores, M. G.
    Arbelbide, J.
    Kornblihtt, L.
    Crisp, R.
    Correa, W.
    Gonzalez, J.
    Bengio, R.
    Narbaitz, M.
    Pardo, L.
    Watman, N.
    Bestach, Y.
    Rosenhain, M.
    Basquiera, A.
    Larripa, I.
    Iastrebner, M.
    Belli, C.
    HAEMATOLOGICA, 2015, 100 : 483 - 483
  • [42] Increased expression of Fas antigen and apoptosis in patients with myelodysplastic syndromes.
    Okada, M
    Okamoto, T
    Saheki, K
    Fujimori, Y
    Takemoto, Y
    Kakisita, E
    BLOOD, 1997, 90 (10) : 893 - 893
  • [43] Study on the burden of abnormal hematopoietic clone of the patients with myelodysplastic syndromes.
    Shao, ZH
    Wang, HQ
    Shi, J
    Cao, YR
    Liu, H
    Bai, H
    Tu, MF
    Xing, LM
    Liu, SH
    Sun, J
    Jia, HR
    BLOOD, 2005, 106 (11) : 305B - 305B
  • [44] The prognostic value of LDH in myelodysplastic syndromes.
    Wimazal, F
    Sperr, WR
    Kundi, M
    Fonatsch, C
    Thalhammer-Scherrer, R
    Wessel, S
    Meidlinger, P
    Schwarzinger, I
    Geissler, K
    Lechner, K
    Valent, P
    BLOOD, 1999, 94 (10) : 288B - 288B
  • [45] Recombinant erythropoietin and survival in myelodysplastic syndromes.
    Musto, P
    BLOOD, 2005, 106 (11) : 713A - 713A
  • [46] Isolated Trisomy 8 in the Myelodysplastic Syndromes.
    Gangat, Naseema
    Greipp, Patricia
    Hanson, Curtis A.
    Hoyer, James
    Chen, Dong
    Ketterling, Rhett P.
    Dingli, David
    BLOOD, 2009, 114 (22) : 1089 - 1089
  • [47] Antithymocyte globulin for the treatment of patients with 'low risk' myelodysplastic syndromes.
    Killick, SB
    Marsh, JC
    Cavenagh, JD
    Mijovic, A
    Mufti, G
    Gordon-Smith, EC
    Bowen, DT
    BLOOD, 1999, 94 (10) : 306A - 307A
  • [48] Involvement of inhibitor of apoptosis protein survivin in the patients with myelodysplastic syndromes.
    Zhen, C
    Bao, HY
    Lin, MF
    Ludwig, WD
    Karawajew, L
    Wuchter, C
    BLOOD, 2002, 100 (11) : 376A - 377A
  • [49] Cutaneous manifestations associated with myelodysplastic syndromes.
    Morand, JJ
    Lightburn, E
    Richard, MA
    Hesse-Bonerandi, S
    Carsuzaa, F
    Grob, JJ
    REVUE DE MEDECINE INTERNE, 2001, 22 (09): : 845 - 853
  • [50] Myelodysplastic syndromes. Clinical and biological advances
    T Hamblin
    Bone Marrow Transplantation, 2006, 37 (8) : 809 - 809
12345